“All-in-One” Therapy for Relapsed Acute Leukemia

While chimeric antigen receptor (CAR) T-cell therapies are now a standard treatment for relapsed or refractory B-cell malignancies, their application in myeloid and T-cell neoplasms has lagged behind, in part due to effects on normal hematopoiesis. Now, investigators report a novel approach of induction therapy with an anti-CD7 CAR T-cell product followed by hematopoietic reconstitution via haploidentical allogeneic hematopoietic stem-cell transplantation (alloHSCT).

Seventeen patients with relapsed CD7-positive acute myeloid leukemia (AML) or T-cell acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma received a haploidentical donor-derived anti-CD7 CAR-T infusion. Of those, 10 patients achieved complete remission with incomplete hemat…